Understanding the pharmacodynamics of a clinically-used β-lactamase inhibitor, avibactam
What is it about?
The paper describes how quantitative PK/PD "targets" were deduced from preclinical experiments that enabled human pharmacokinetic simulations to predict the achievement of efficacious antibacterial activity in patients that would be yielded by different dosing regimes of 3 β-lactam/avibactam (a β-lactamase inhibitor) drug combinations: ceftazidime (a cephalosporin β-lactam)/avibactam, aztreonam (a monobactam β-lactam)/avibactam, and ceftaroline fosamil (a further cephalosporin β-lactam)/avibactam.
Why is it important?
The work was a key step in preparing for clinical trials of ceftazidime/avibactam, aztreonam/avibactam, and ceftaroline fosamil/avibactam. These drugs overcome many important β-lactamase-mediated resistances to ceftazidime, aztreonam, and ceftaroline fosamil in the Gram-negative bacteria, Pseudomonas aeruginosa and the Enterobacteriaceae.
The following have contributed to this page: Wright Nichols